The $40 million Department of Defense research program into restoring memory will use NeuroPace's implantable neurostimulator, a move that the company said could help it expand the product's indications beyond epilepsy.
A new three-drug combo treatment for tuberculosis better eradicated the disease than standard therapy in a midstage trial, showing particular promise for patients with HIV as it rolls into Phase III development.
Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology is expanding its R&D collaboration with Intrexon to include the personalized immuno-oncology technology.
Patient monitoring technology is a growing niche within the industry, with big and small operations looking for their cut of the profits. A new device from a team of nurses, engineers and computer scientists takes the trend one step further, monitoring a patient's health through a bandage.
Scientists from the Broad Institute are unveiling new genomic findings from thousands of schizophrenia patients that could lead to new molecular targets. And, thanks to the philanthropist Ted Stanley, they'll have $650 million to help find out.
This morning Atlas Venture and New Enterprise Associates announced that they have committed $29.4 million to launch Synlogic, a new Cambridge, MA-based upstart initially seeded last fall that has set out to build a platform that can create therapeutic microbes.
Baltimore-based Cerecor has gathered up the first half of a $33 million B round, with plans to devote much of that money to a midstage development program for an experimental depression therapy recently punted by a restructuring Merck.
People suffering from limited dexterity in their hands may soon get an extra set of fingers to help navigate daily life with a device researchers at MIT have developed that is worn on the wrist and uses a unique algorithm to mimic human movement.
A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.
The deal gives Google a partner with healthcare experience to commercialize the glucose-recording contact lens technology it unveiled earlier this year.